Minireview: Recent developments in the physiology and pathology of the lysophosphatidylinositol-sensitive receptor GPR55

Molecular Endocrinology

Volumn 25, Issue 11, 2011, Pages 1835-1848

  Henstridge, Christopher M ^a   Balenga, Nariman A B ^b   Kargl, Julia ^b   Andradas, Clara ^c   Brown, Andrew J ^d   Irving, Andrew ^e   Sanchez, Cristina ^c   Waldhoer, Maria ^b  

^a INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

^c UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^d GLAXOSMITHKLINE   (United Kingdom)

^e UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 55; MESSENGER RNA; UNCLASSIFIED DRUG;

BLOOD; BONE; CELL TYPE; HUMAN; KIDNEY; MAST CELL; NEOPLASM; NERVOUS SYSTEM; NONHUMAN; NUCLEOTIDE SEQUENCE; PAIN; PATHOPHYSIOLOGY; PHYLOGENY; PHYSIOLOGY; PLACENTA; PRIORITY JOURNAL; REVIEW; TISSUE TYPES; VASCULARIZATION;

ANIMALS; HUMANS; LYSOPHOSPHOLIPIDS; RECEPTORS, CANNABINOID; RECEPTORS, G-PROTEIN-COUPLED;

EID: 80054987727     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2011-1197     Document Type: Review

References (121)

1. Mackie K, Stella N 2006 Cannabinoid receptors and endocannabi-noids: evidence for new players. AAPS J 8:E298-E306
2. Brown AJ 2007 Novel cannabinoid receptors. Br J Pharmacol 152:567-575
3. Baker D, Pryce G, Davies WL, Hiley CR 2006 In silico patent searching reveals a new cannabinoid receptor. Trends Pharmacol Sci 27:1-4
4. Oka S, Nakajima K, Yamashita A, Kishimoto S, Sugiura T 2007 Identification of GPR55 as a lysophosphatidylinositol receptor. Biochem Biophys Res Commun 362:928-934
5. Brown AJ, Robin Hiley C 2009 Is GPR55 an anandamide receptor? Vitam Horm 81:111-137
6. Godlewski G, Offertaler L, Wagner JA, Kunos G 2009 Receptors for acylethanolamides-GPR55 and GPR119. Prostaglandins Other Lipid Mediat 89:105-111
7. Moriconi A, Cerbara I, Maccarrone M, Topai A 2010 GPR55: current knowledge and future perspectives of a purported "type-3" cannabinoid receptor. Curr Med Chem 17:1411-1429
8. Nevalainen T, Irving AJ 2010 GPR55, a lysophosphatidylinositol receptor with cannabinoid sensitivity? Curr Top Med Chem 10: 799-813
9. Ross RA 2009 The enigmatic pharmacology of GPR55. Trends Pharmacol Sci 30:156-163
10. Sharir H, Abood ME 2010 Pharmacological characterization of GPR55, a putative cannabinoid receptor. Pharmacol Ther 126: 301-313
11. Keenan RW, Hokin LE 1962 The identification of lysophosphatidylinositol and its enzymic conversion to phosphatidylinositol. Biochim Biophys Acta 60:428-430
12. Keenan RW, Hokin LE 1964 The enzymatic acylation of lysophosphatidylinositol. J Biol Chem 239:2123-2129
13. Metz SA 1986 Lysophosphatidylinositol, but not lysophosphatidic acid, stimulates insulin release. A possible role for phospholipase A2 but not de novo synthesis of lysophospholipid in pancreatic islet function. Biochem Biophys Res Commun 138:720-727
14. Metz SA 1988 Mobilization of cellular Ca2+ by lysophospholipids in rat islets of Langerhans. Biochim Biophys Acta 968:239-252
15. Zoeller RA, Wightman PD, Anderson MS, Raetz CR 1987 Accumulation of lysophosphatidylinositol in RAW 264.7 macrophage tumor cells stimulated by lipid A precursors. J Biol Chem 262: 17212-17220
16. Baran DT, Kelly AM 1988 Lysophosphatidylinositol: a potential mediator of 1,25-dihydroxyvitamin D-induced increments in he-patocyte cytosolic calcium. Endocrinology 122:930-934
17. Smith DM, Waite M 1992 Phosphatidylinositol hydrolysis by phospholipase A2 and C activities in human peripheral blood neutrophils. J Leukoc Biol 52:670-678
18. Falasca M, Corda D 1994 Elevated levels and mitogenic activity of lysophosphatidylinositol in k-ras-transformed epithelial cells. Eur J Biochem 221:383-389
19. Falasca M, Silletta MG, Carvelli A, Di Francesco AL, Fusco A, Ramakrishna V, Corda D 1995 Signalling pathways involved in the mitogenic action of lysophosphatidylinositol. Oncogene 10: 2113-2124
20. Xiao Y, Chen Y, Kennedy AW, Belinson J, Xu Y 2000 Evaluation of plasma lysophospholipids for diagnostic significance using elec-trospray ionization mass spectrometry (ESI-MS) analyses. Ann NY Acad Sci 905:242-259
21. Shen Z, Wu M, Elson P, Kennedy AW, Belinson J, Casey G, Xu Y 2001 Fatty acid composition of lysophosphatidic acid and lyso- phosphatidylinositol in plasma from patients with ovarian cancer and other gynecological diseases. Gynecol Oncol 83:25-30
22. Sutphen R, Xu Y, Wilbanks GD, Fiorica J, Grendys Jr EC, LaPolla JP, Arango H, Hoffman MS, Martino M, Wakeley K, Griffin D, Blanco RW, Cantor AB, Xiao YJ, Krischer JP 2004 Lysophospho-lipids are potential biomarkers of ovarian cancer. Cancer Epidemiol Biomarkers Prev 13:1185-1191
23. Blondeau N, Lauritzen I, Widmann C, Lazdunski M, Heurteaux C 2002 A potent protective role of lysophospholipids against global cerebral ischemia and glutamate excitotoxicity in neuronal cul tures. J Cereb Blood Flow Metab 22:821-834
24. Maingret F, Patel AJ, Lesage F, Lazdunski M, Honore E 2000 Lysophospholipids open the two-pore domain mechano-gated K(+) channels TREK-1 and TRAAK. J Biol Chem 275:10128-10133
25. Sawzdargo M, Nguyen T, Lee DK, Lynch KR, Cheng R, Heng HH, George SR, O'Dowd BF 1999 Identification and cloning of three novel human G protein-coupled receptor genes GPR52, PsiGPR53 and GPR55: GPR55 is extensively expressed in human brain. Brain Res Mol Brain Res 64:193-198
26. Ryberg E, Larsson N, Sjogren S, Hjorth S, Hermansson NO, Le-onova J, Elebring T, Nilsson K, Drmota T, Greasley PJ 2007 The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 152:1092-1101
27. McPartland JM, Glass M, Matias I, Norris RW, Kilpatrick CW 2007 A shifted repertoire of endocannabinoid genes in the ze-brafish (Danio rerio). Mol Genet Genomics 277:555-570
28. Rovati GE, Capra V, Neubig RR 2007 The highly conserved DRY motif of class A G protein-coupled receptors: beyond the ground state. Mol Pharmacol 71:959-964
29. Kotsikorou E, Madrigal KE, Hurst DP, Sharir H, Lynch DL, Heynen-Genel S, Milan LB, Chung TD, Seltzman HH, Bai Y, Caron MG, Barak L, Abood ME, Reggio PH 2011 Identification of the GPR55 agonist binding site using a novel set of high potency GPR55 selective ligands. Biochemistry 50:5633-5647
30. Petitet F, Donlan M, Michel A 2006 GPR55 as a new cannabinoid receptor: still a long way to prove it. Chem Biol Drug Des 67:252-253
31. Cherezov V, Rosenbaum DM, Hanson MA, Rasmussen SG, Thian FS, Kobilka TS, Choi HJ, Kuhn P, Weis WI, Kobilka BK, Stevens RC 2007 High-resolution crystal structure of an engineered human β2-adrenergic G protein-coupled receptor. Science 318: 1258-1265
32. Hurst DP, Grossfield A, Lynch DL, Feller S, Romo TD, Gawrisch K, Pitman MC, Reggio PH 2010 A lipid pathway for ligand binding is necessary for a cannabinoid G protein-coupled receptor. J Biol Chem 285:17954-17964
33. Pei Y, Mercier RW, Anday JK, Thakur GA, Zvonok AM, Hurst D, Reggio PH, Janero DR, Makriyannis A 2008 Ligand-binding architecture of human CB2 cannabinoid receptor: evidence for receptor subtype-specific binding motif and modeling GPCR activation. Chem Biol 15:1207-1219
34. Picone RP, Khanolkar AD, Xu W, Ayotte LA, Thakur GA, Hurst DP, Abood ME, Reggio PH, Fournier DJ, Makriyannis A 2005 (-)-7'-Isothiocyanato-11-hydroxy-1',1'-dimethylheptylhexahyd-rocannabinol (AM841), a high-affinity electrophilic ligand, interacts covalently with a cysteine in helix six and activates the CB1 cannabinoid receptor. Mol Pharmacol 68:1623-1635
35. Kotsikorou E, Lynch DL, Abood ME, Reggio PH 2011 Lipid bi-layer molecular dynamics study of lipid-derived agonists of the putative cannabinoid receptor, GPR55. Chem Phys Lipids 164: 131-143
36. Pertwee RG, Howlett AC, Abood ME, Alexander SP, Di Marzo V, Elphick MR, Greasley PJ, Hansen HS, Kunos G, Mackie K, Mechoulam R, Ross RA 2010 International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB1 and CB2. Pharmacol Rev 62:588-631
37. Zhang X, Maor Y, Wang JF, Kunos G, Groopman JE 2010 Endocannabinoid-like N-arachidonoyl serine is a novel pro-angio-genic mediator. Br J Pharmacol 160:1583-1594
38. Brown AJ, Daniels DA, Kassim M, Brown S, Haslam CP, Terrell VR, Brown J, Nichols PL, Staton PC, Wise A, Dowell SJ 2011 Pharmacology of GPR55 in yeast and identification of GSK494581A as a mixed-activity glycine transporter subtype 1 inhibitor and GPR55 agonist. J Pharmacol Exp Ther 337:236-246
39. Henstridge CM, Balenga NA, Ford LA, Ross RA, Waldhoer M, Irving AJ 2009 The GPR55 ligand L-a-lysophosphatidylinositol promotes RhoA-dependent Ca2 + signaling and NFAT activation. FASEB J 23:183-193
40. Kapur A, Zhao P, Sharir H, Bai Y, Caron MG, Barak LS, Abood ME 2009 Atypical responsiveness of the orphan receptor GPR55 to cannabinoid ligands. J Biol Chem 284:29817-29827
41. Henstridge CM, Balenga NA, Schroder R, Kargl JK, Platzer W, Martini L, Arthur S, Penman J, Whistler JL, Kostenis E, Waldhoer M, Irving AJ 2010 GPR55 ligands promote receptor coupling to multiple signalling pathways. Br J Pharmacol 160:604-614
42. Yin H, Chu A, Li W, Wang B, Shelton F, Otero F, Nguyen DG, Caldwell JS, Chen YA 2009 Lipid G protein-coupled receptor ligand identification using β-arrestin PathHunter assay. J Biol Chem 284:12328-12338
43. Ford LA, Roelofs AJ, Anavi-Goffer S, Mowat L, Simpson DG, Irving AJ, Rogers MJ, Rajnicek AM, Ross RA 2010 A role for L-a-lysophosphatidylinositol and GPR55 in the modulation of migration, orientation and polarization of human breast cancer cells. Br J Pharmacol 160:762-771
44. Kargl J, Balenga N, Platzer W, Martini L, Whistler J, Waldhoer M 30 June 2011 The GPCR-associated sorting protein 1 regulates ligand-induced downregulation of GPR55. Br J Pharmacol 10.1111/j.1476-5381.2011.01562.x
45. Baltrusch S, Lenzen S 2007 Regulation of [Ca2+]i oscillations in mouse pancreatic islets by adrenergic agonists. Biochem Biophys Res Commun 363:1038-1043
46. Soria B, Martin F 1998 Cytosolic calcium oscillations and insulin release in pancreatic islets of Langerhans. Diabetes Metab 24: 37-40
47. Schroder R, Janssen N, Schmidt J, Kebig A, Merten N, Hennen S, Müller A, Blattermann S, Mohr-Andra M, Zahn S, Wenzel J, Smith NJ, Gomeza J, Drewke C, Milligan G, Mohr K, Kostenis E 2010 Deconvolution of complex G protein-coupled receptor signaling in live cells using dynamic mass redistribution measurements. Nat Biotechnol 28:943-949
48. Balenga NA, Aflaki E, Kargl J, Platzer W, Schroder R, Blattermann S, Kostenis E, Brown AJ, Heinemann A, Waldhoer M 5 April 2011 GPR55 regulates cannabinoid 2 receptor-mediated responses in human neutrophils. Cell Res 10.1038/cr.2011.60
49. Lauckner JE, Jensen JB, Chen HY, Lu HC, Hille B, Mackie K 2008 GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proc Natl Acad Sci USA 105:2699-2704
50. Oka S, Kimura S, Toshida T, Ota R, Yamashita A, Sugiura T 2010 Lysophosphatidylinositol induces rapid phosphorylation of p38 mitogen-activated protein kinase and activating transcription factor 2 in HEK293 cells expressing GPR55 and IM-9 lymphoblas-toid cells. J Biochem 147:671-678
51. Pietr M, Kozela E, Levy R, Rimmerman N, Lin YH, Stella N, Vogel Z, Juknat A 2009 Differential changes in GPR55 during microglial cell activation. FEBS Lett 583:2071-2076
52. Pineiro R, Maffucci T, Falasca M 2011 The putative cannabinoid receptor GPR55 defines a novel autocrine loop in cancer cell proliferation. Oncogene 30:142-152
53. Waldeck-Weiermair M, Zoratti C, Osibow K, Balenga N, Goess-nitzer E, Waldhoer M, Malli R, Graier WF 2008 Integrin clustering enables anandamide-induced Ca2+ signaling in endothelial cells via GPR55 by protection against CB1-receptor-triggered repression. J Cell Sci 121:1704-1717
54. Katona I, Freund TF 2008 Endocannabinoid signaling as a synaptic circuit breaker in neurological disease. Nat Med 14:923-930
55. Navarrete M, Araque A 2010 Endocannabinoids potentiate synaptic transmission through stimulation of astrocytes. Neuron 68: 113-126
56. Stella N 2010 Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas. Glia 58:1017-1030
57. Breivogel CS, Griffin G, Di Marzo V, Martin BR 2001 Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol Pharmacol 60:155-163
58. Rouach N, Nicoll RA 2003 Endocannabinoids contribute to short-term but not long-term mGluR-induced depression in the hippocampus. Eur J Neurosci 18:1017-1020
59. Hajos N, Ledent C, Freund TF 2001 Novel cannabinoid-sensitive receptor mediates inhibition of glutamatergic synaptic transmission in the hippocampus. Neuroscience United States 106:1-4
60. Hajos N, Freund TF 2002 Distinct cannabinoid sensitive receptors regulate hippocampal excitation and inhibition. Chem Phys Lipids 121:73-82
61. Pistis M, Perra S, Pillolla G, Melis M, Gessa GL, Muntoni AL 2004 Cannabinoids modulate neuronal firing in the rat basolateral amygdala: evidence for CB1- and non-CB1-mediated actions. Neuropharmacology 46:115-125
62. Brown AJ, Wise A 2001 GlaxoSmithKline. Identification of modulators of GPR55 activity 2001. Patent WO/2001/86305
63. Staton PC, Hatcher JP, Walker DJ, Morrison AD, Shapland EM, Hughes JP, Chong E, Mander PK, Green PJ, Billinton A, Fulley-love M, Lancaster HC, Smith JC, Bailey LT, Wise A, Brown AJ, Richardson JC, Chessell IP 2008 The putative cannabinoid receptor GPR55 plays a role in mechanical hyperalgesia associated with inflammatory and neuropathic pain. Pain 139:225-236
64. Harkany T, Mackie K, Doherty P 2008 Wiring and firing neuronal networks: endocannabinoids take center stage. Curr Opin Neuro-biol 18:338-345
65. Berghuis P, Rajnicek AM, Morozov YM, Ross RA, Mulder J, Urban GM, Monory K, Marsicano G, Matteoli M, Canty A, Irving AJ, Katona I, Yanagawa Y, Rakic P, Lutz B, Mackie K, Harkany T 2007 Hardwiring the brain: endocannabinoids shape neuronal connectivity. Science (New York, NY) 316:1212-1216
66. Wu CS, Zhu J, Wager-Miller J, Wang S, O'Leary D, Monory K, Lutz B, Mackie K, Lu HC 2010 Requirement of cannabinoid CB(1) receptors in cortical pyramidal neurons for appropriate development of corticothalamic and thalamocortical projections. Eur J Neurosci 32:693-706
67. Chiba T, Ueno S, Obara Y, Nakahata N 2011 A synthetic cannabinoid, CP55940, inhibits lipopolysaccharide-induced cytokine mRNA expression in a cannabinoid receptor-independent mechanism in rat cerebellar granule cells. J Pharm Pharmacol 63:636-647
68. Ma MT, Yeo JF, Farooqui AA, Zhang J, Chen P, Ong WY 2010 Differential effects of lysophospholipids on exocytosis in rat PC12 cells. J Neural Transm 117:301-308
69. Schuelert N, McDougall JJ 2011 The abnormal cannabidiol analogue O-1602 reduces nociception in a rat model of acute arthritis via the putative cannabinoid receptor GPR55. Neurosci Lett 500: 72-76
70. O'Sullivan SE, Kendall DA, Randall MD 2005 The effects of A9-tetrahydrocannabinol in rat mesenteric vasculature, and its interactions with the endocannabinoid anandamide. Br J Pharmacol 145:514-526
71. Jarai Z, Wagner JA, Varga K, Lake KD, Compton DR, Martin BR, Zimmer AM, Bonner TI, Buckley NE, Mezey E, Razdan RK, Zimmer A, Kunos G 1999 Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc Natl Acad Sci USA 96:14136-14141
72. Offertaler L, Mo FM, Batkai S, Liu J, Begg M, Razdan RK, Martin BR, Bukoski RD, Kunos G 2003 Selective ligands and cellular effectors of a G protein-coupled endothelial cannabinoid receptor. Mol Pharmacol 63:699-705
73. Ho WS, Hiley CR 2003 Vasodilator actions of abnormal-canna-bidiol in rat isolated small mesenteric artery. Br J Pharmacol 138: 1320-1332
74. Wagner JA, Varga K, Jarai Z, Kunos G 1999 Mesenteric vasodilation mediated by endothelial anandamide receptors. Hypertension 33:429-434
75. Johns DG, Behm DJ, Walker DJ, Ao Z, Shapland EM, Daniels DA, Riddick M, Dowell S, Staton PC, Green P, Shabon U, Bao W, Aiyar N, Yue TL, Brown AJ, Morrison AD, Douglas SA 2007 The novel endocannabinoid receptor GPR55 is activated by atypical cannabinoids but does not mediate their vasodilator effects. Br J Pharmacol 152:825-831
76. Daly CJ, Ross RA, Whyte J, Henstridge CM, Irving AJ, McGrath JC 2010 Fluorescent ligand binding reveals heterogeneous distribution of adrenoceptors and 'cannabinoid-like' receptors in small arteries. Br J Pharmacol 159:787-796
77. Kaya H, Patton GM, Hong SL 1989 Bradykinin-induced activation of phospholipase A2 is independent of the activation of poly-phosphoinositide-hydrolyzing phospholipase C. J Biol Chem 264: 4972-4977
78. Deutsch DG, Goligorsky MS, Schmid PC, Krebsbach RJ, Schmid HH, Das SK, Dey SK, Arreaza G, Thorup C, Stefano G, Moore LC 1997 Production and physiological actions of anandamide in the vasculature of the rat kidney. J Clin Invest 100:1538-1546
79. Bondarenko A, Waldeck-Weiermair M, Naghdi S, Poteser M, Malli R, Graier WF 2010 GPR55-dependent and -independent ion signalling in response to lysophosphatidylinositol in endothelial cells. Br J Pharmacol 161:308-320
80. Bondarenko AI, Malli R, Graier WF 2011 The GPR55 agonist lysophosphatidylinositol acts as an intracellular messenger and bidirectionally modulates Ca2+ -activated large-conductance K+ channels in endothelial cells. Pflugers Arch 461:177-189
81. Bondarenko AI, Malli R, Graier WF 2011 The GPR55 agonist lysophosphatidylinositol directly activates intermediate-conductance Ca(2 +)-activated K (+) channels. Pflugers Arch 462:245-255
82. Pacher P, Mechoulam R 2011 Is lipid signaling through cannabinoid 2 receptors part of a protective system? Prog Lipid Res 50: 193-211
83. Tanasescu R, Constantinescu CS 2010 Cannabinoids and the immune system: an overview. Immunobiology 215:588-597
84. McHugh D, Ross RA 2009 Endogenous cannabinoids and neutrophil chemotaxis. Vitam Horm 81:337-365
85. McHugh D, Hu SS, Rimmerman N, Juknat A, Vogel Z, Walker JM, Bradshaw HB 2010 N-arachidonoyl glycine, an abundant endogenous lipid, potently drives directed cellular migration through GPR18, the putative abnormal cannabidiol receptor. BMC Neurosci 11:44
86. Schicho R, Bashashati M, Bawa M, McHugh D, Saur D, Hu HM, Zimmer A, Lutz B, Mackie K, Bradshaw HB, McCafferty DM, Sharkey KA, Storr M 2011 The atypical cannabinoid O-1602 protects against experimental colitis and inhibits neutrophil recruitment. Inflamm Bowel Dis 17:1651-1664
87. Whyte LS, Ryberg E, Sims NA, Ridge SA, Mackie K, Greasley PJ, Ross RA, Rogers MJ 2009 The putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivo. Proc Natl Acad Sci USA 106:16511-16516
88. Sims NA, Gooi JH 2008 Bone remodeling: multiple cellular interactions required for coupling of bone formation and resorption. Semin Cell Dev Biol 19:444-451
89. Andersson J, Sophocleous A, Zhou Y, Rischitor G, Ralston S, Salter D 2011 Expression of cannabinoid receptors by human articular chondrocytes. Bone 48:S141-S141
90. Pertwee RG 2010 Receptors and channels targeted by synthetic cannabinoid receptor agonists and antagonists. Curr Med Chem 17:1360-1381
91. Guzmán M 2003 Cannabinoids: potential anticancer agents. Nat Rev Cancer 3:745-755
92. Sarfaraz S, Adhami VM, Syed DN, Afaq F, Mukhtar H 2008 Cannabinoids for cancer treatment: progress and promise. Cancer Res 68:339-342
93. Velasco G, Carracedo A, Blázquez C, Lorente M, Aguado T, Haro A, Sánchez C, Galve-Roperh I, Guzmán M 2007 Cannabinoids and gliomas. Mol Neurobiol 36:60-67
94. Caffarel MM, Andradas C, Mira E, Pérez-Gómez E, Cerutti C, Moreno-Bueno G, Flores JM, García-Real I, Palacios J, Mañes S, Guzmán M, Sánchez C 2010 Cannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition. Mol Cancer 9:196
95. Qamri Z, Preet A, Nasser MW, Bass CE, Leone G, Barsky SH, Ganju RK 2009 Synthetic cannabinoid receptor agonists inhibit tumor growth and metastasis of breast cancer. Mol Cancer Ther 8:3117-3129
96. Wang D, Wang H, Ning W, Backlund MG, Dey SK, DuBois RN 2008 Loss of cannabinoid receptor 1 accelerates intestinal tumor growth. Cancer Res 68:6468-6476
97. Xiao YJ, Schwartz B, Washington M, Kennedy A, Webster K, Belinson J, Xu Y 2001 Electrospray ionization mass spectrometry analysis of lysophospholipids in human ascitic fluids: comparison of the lysophospholipid contents in malignant vs nonmalignant ascitic fluids. Anal Biochem 290:302-313
98. Oka S, Toshida T, Maruyama K, Nakajima K, Yamashita A, Sugiura T 2009 2-Arachidonoyl-sn-glycero-3-phosphoinositol: a possible natural ligand for GPR55. J Biochem 145:13-20
99. Falasca M, Iurisci C, Carvelli A, Sacchetti A, Corda D 1998 Release of the mitogen lysophosphatidylinositol from H-Ras-trans-formed fibroblasts; a possible mechanism of autocrine control of cell proliferation. Oncogene 16:2357-2365
100. Kelly P, Moeller BJ, Juneja J, Booden MA, Der CJ, Daaka Y, Dewhirst MW, Fields TA, Casey PJ 2006 The G12 family of heterotrimeric G proteins promotes breast cancer invasion and metastasis. Proc Natl Acad Sci USA 103:8173-8178
101. Lappano R, Maggiolini M 2011 G protein-coupled receptors: novel targets for drug discovery in cancer. Nat Rev Drug Discov 10:47-60
102. Andradas C, Caffarel MM, Pérez-Gómez E, Salazar M, Lorente M, Velasco G, Guzmán M, Sánchez C 2011 The orphanGprotein-coupled receptor GPR55 promotes cancer cell proliferation via ERK. Oncogene 30:245-252
103. Huang L, Ramirez JC, Frampton GA, Golden LE, Quinn MA, Pae HY, Horvat D, Liang LJ, DeMorrow S 2011 Anandamide exerts its antiproliferative actions on cholangiocarcinoma by activation of the GPR55 receptor. Lab Invest 91:1007-1017
104. Cantarella G, Scollo M, Lempereur L, Saccani-Jotti G, Basile F, Bernardini R 2011 Endocannabinoids inhibit release of nerve growth factor by inflammation-activated mast cells. Biochem Pharmacol 82:380-388
105. Fonseca BM, Teixeira NA, Almada M, Taylor AH, Konje JC, Correia-da-Silva G 2011 Modulation of the novel cannabinoid receptor-GPR55-during rat fetoplacental development. Placenta 32:462-469
106. Fonseca BM, Correia-da-Silva G, Taylor AH, Lam PM, Marczylo TH, Konje JC, Bell SC, Teixeira NA 2010 N-acylethanolamine levels and expression of their metabolizing enzymes during pregnancy. Endocrinology 151:3965-3974
107. Matias I, Di Marzo V 2007 Endocannabinoids and the control of energy balance. Trends Endocrinol Metab 18:27-37
108. Janiak P, Poirier B, Bidouard JP, Cadrouvele C, Pierre F, Gouraud L, Barbosa I, Dedio J, Maffrand JP, Le Fur G, O'Connor S, Herbert JM 2007 Blockade of cannabinoid CB1 receptors improves renal function, metabolic profile, and increased survival of obese Zucker rats. Kidney Int 72:1345-1357
109. Jenkin KA, McAinch AJ, Grinfeld E, Hryciw DH 2010 Role for cannabinoid receptors in human proximal tubular hypertrophy. Cell Physiol Biochem 26:879-886
110. Chun J, Hla T, Lynch KR, Spiegel S, Moolenaar WH 2010 International Union of Basic and Clinical Pharmacology. LXXVIII. Lysophospholipid receptor nomenclature. Pharmacol Rev 62: 579-587
111. Takabe K, Paugh SW, Milstien S, Spiegel S 2008 "Inside-out" signaling of sphingosine-1-phosphate: therapeutic targets. Pharmacol Rev 60:181-195
112. Xu Y, Xiao YJ, Zhu K, Baudhuin LM, Lu J, Hong G, Kim KS, Cristina KL, Song L, S Williams F, Elson P, Markman M, Belinson J 2003 Unfolding the pathophysiological role of bioactive lyso-phospholipids. Curr Drug Targets Immune Endocr Metab Disord 3:23-32
113. Panupinthu N, Lee HY, Mills GB 2010 Lysophosphatidic acid production and action: critical new players in breast cancer initiation and progression. Br J Cancer 102:941-946
114. Lin ME, Herr DR, Chun J 2010 Lysophosphatidic acid (LPA) receptors: signaling properties and disease relevance. Prostaglandins Other Lipid Mediat 91:130-138
115. Brinkmann V, Billich A, Baumruker T, Heining P, Schmouder R, Francis G, Aradhye S, Burtin P 2010 Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov 9:883-897
116. Ross RA 2011 L-a-Lysophosphatidylinositol meets GPR55: a deadly relationship. Trends Pharmacol Sci 32:265-269
117. Malfait AM, Gallily R, Sumariwalla PF, Malik AS, Andreakos E, Mechoulam R, Feldmann M 2000 The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci USA 97:9561-9566
118. Chapman CG, Meadows HJ, Godden RJ, Campbell DA, Duckworth M, Kelsell RE, Murdock PR, Randall AD, Rennie GI, Gloger IS 2000 Cloning, localisation and functional expression of a novel human, cerebellum specific, two pore domain potassium channel. Brain Res Mol Brain Res 82:74-83
119. Moore DJ, Murdock PR, Watson JM, Faull RL, Waldvogel HJ, Szekeres PG, Wilson S, Freeman KB, Emson PC 2003 GPR105, a novel Gi/o-coupled UDP-glucose receptor expressed on brain glia and peripheral immune cells, is regulated by immunologic challenge: possible role in neuroimmune function. Brain Res Mol Brain Res 118:10-23
120. Moore DJ, Chambers JK, Wahlin JP, Tan KB, Moore GB, Jenkins O, Emson PC, Murdock PR 2001 Expression pattern of human P2Y receptor subtypes: a quantitative reverse transcription-poly-merase chain reaction study. Biochim Biophys Acta 1521:107-119
121. Cohen-Yeshurun A, Trembovler V, Alexandrovich A, Ryberg E, Greasley PJ, Mechoulam R, Shohami E, Leker RR 2011 N-arachi-donoyl-L-serine is neuroprotective after traumatic brain injury by reducing apoptosis. J Cereb Blood Flow Metab 8:1768-1777